taniborbactam

bicyclic boronate that is a beta-lactamase inhibitor

Also Known As:

(3R)-3-(((trans-4-((2-Aminoethyl)amino)cyclohexyl)acetyl)amino)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic acid; 2H-1,2-Benzoxaborin-8-carboxylic acid, 3-((2-(trans-4-((2-aminoethyl)amino)cyclohexyl)acetyl)amino)-3,4-dihydro-2-hydroxy-, (3R)-; VNRX-5133

Networked: 16 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Nicolau, David P: 2 articles (01/2022 - 12/2020)
2.	Benvenuti, Manuela: 2 articles (01/2020 - 01/2020)
3.	Burns, Christopher J: 2 articles (01/2020 - 01/2020)
4.	Cusick, Susan M: 2 articles (01/2020 - 01/2020)
5.	Daigle, Denis M: 2 articles (01/2020 - 01/2020)
6.	De Luca, Filomena: 2 articles (01/2020 - 01/2020)
7.	Docquier, Jean-Denis: 2 articles (01/2020 - 01/2020)
8.	Hamrick, Jodie C: 2 articles (01/2020 - 01/2020)
9.	Jackson, Randy W: 2 articles (01/2020 - 01/2020)
10.	Liu, Bin: 2 articles (01/2020 - 01/2020)

Related Diseases

1.	Urinary Tract Infections (Urinary Tract Infection) 12/01/2022 - "Cefepime-taniborbactam possesses in-vitro potency against a range of troubling pathogens and we await further information on a recently completed study on complicated urinary tract infection. " 12/01/2020 - "In combination with cefepime, the bicyclic boronate taniborbactam is in phase 3 clinical trials for treatment of complicated urinary tract infections. " 01/01/2022 - "Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model." 01/01/2020 - "Taniborbactam's superior breadth of activity, when paired with cefepime or meropenem, suggests these β-lactam/β-lactamase inhibitor combinations could be promising candidates for treating urinary tract infections caused by ESBL and/or AmpC, KPC or NDM-producing Enterobacteriaceae or P. " 01/01/2021 - "The efficacy of taniborbactam and QPX7728 is compared with the cyclic boronate inhibitor vaborbactam, which is the first boron-based β-lactamase inhibitor approved by the FDA in combination with meropenem for the treatment of complicated urinary tract infections."
2.	Infections 12/01/2020 - "Using a neutropenic murine thigh infection model, we aimed to determine the pharmacokinetic/pharmacodynamic index, relative to taniborbactam exposure, that correlated most closely with the efficacy of the cefepime/taniborbactam combination and the magnitude of index required for efficacy against serine-β-lactamase-producing strains. " 01/01/2022 - "Taniborbactam, an investigational β-lactamase inhibitor that is active against both serine- and metallo-β-lactamases, is being developed in combination with cefepime to treat serious infections caused by multidrug-resistant Gram-negative bacteria. " 11/01/2021 - "The combinations cefepime-taniborbactam and meropenem-taniborbactam are promising alternative treatment options for infections by MBL-producing isolates." 10/18/2021 - "Taniborbactam (formerly VNRX-5133), an investigational β-lactamase inhibitor active against both serine- and metallo-β-lactamases, is being developed in combination with cefepime to treat serious infections caused by multidrug-resistant Gram-negative bacteria. " 12/01/2020 - "Cefepime/taniborbactam is a cephalosporin/cyclic boronate β-lactamase inhibitor combination under development for the treatment of infections due to MDR Enterobacterales and Pseudomonas aeruginosa. "
3.	Pneumonia (Pneumonitis) 01/01/2023 - "The observed bronchopulmonary exposures of taniborbactam and cefepime can be employed to design optimal dosing regimens for clinical trials in patients with pneumonia." 01/01/2023 - "aeruginosa isolates with cefepime/taniborbactam MICs up to and including 16 mg/L in the pneumonia model. " 01/01/2023 - "A murine pneumonia model was used to characterize cefepime/taniborbactam in vivo pharmacodynamics against Enterobacterales and Pseudomonas aeruginosa strains. " 01/01/2023 - "In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model."
4.	Headache (Headaches) 10/18/2021 - "The most common adverse event in both placebo- and taniborbactam-treated subjects was headache. "
5.	Cystic Fibrosis (Mucoviscidosis) 09/28/2023 - "Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States."

Related Drugs and Biologics

1.	Cefepime (Maxipime)
2.	Serine (L-Serine)
3.	Meropenem (Merrem)
4.	Boron
5.	QPX7728
6.	vaborbactam
7.	Carbapenems (Carbapenem Antibiotics)
8.	Tazobactam Drug Combination Piperacillin (Zosyn)
9.	enmetazobactam
10.	Cephalosporins (Cephalosporin Antibiotics)